Metis TechBio Co (7666) investor relations material

Executive summary

• Revenue surged 13,399% year-over-year to RMB154.3 million, driven by major licensing and collaboration agreements.

• Adjusted net loss (non-IFRS) narrowed by 56.4% to RMB51.1 million, reflecting improved operational efficiency and milestone payments.

• Significant progress in AI-driven platforms (AiLNP, AiProtein, AiRNA, AiTEM) and expansion of the self-developed pipeline, with multiple candidates advancing in clinical and preclinical stages.

• Landmark global licensing deal for MTS-128 with Boulevard Bio, potential value over US$1.6 billion, and new collaborations with BioThunder AG, GenTurn Life, Edibeck, and Hengrui Pharma.

Financial highlights

• Revenue: RMB154.3 million (up from RMB1.14 million), mainly from collaboration agreements.

• Loss for the period: RMB153.2 million, a 20% reduction year-over-year.

• Adjusted net loss: RMB51.1 million, down 56.4% year-over-year.

• R&D expenses: RMB172.4 million, up 48.1% due to increased investment in pipeline and technology.

• Cash and cash equivalents: RMB2,527.3 million as of June 30, 2026.

• Net cash inflow from financing activities: RMB2,092.7 million, mainly from the Global Offering.

Outlook and guidance

• Focus on advancing AI4S, Biological AI, and Scaling Law to drive R&D efficiency and innovation.

• Long-term strategy targets cell reprogramming and end-to-end capabilities from molecular design to cell-fate regulation.

• Expected to meet revenue requirements under HKEX Rule 18C.03(4) in 2027.